NeuroMetrix Inc (NURO) USD0.0001

Sell:$4.17Buy:$4.81$0.04 (0.80%)

Prices delayed by at least 15 minutes
Sell:$4.17
Buy:$4.81
Change:$0.04 (0.80%)
Prices delayed by at least 15 minutes
Sell:$4.17
Buy:$4.81
Change:$0.04 (0.80%)
Prices delayed by at least 15 minutes

Company Information

About this company

NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Key people

Shai N. Gozani
Chairman of the Board, President, Chief Executive Officer, Secretary
Thomas T. Higgins
Chief Financial Officer, Senior Vice President, Treasurer
David E. Goodman
Independent Director
Joshua S. Horowitz
Independent Director
Nancy E. Katz
Independent Director
David Van Avermaete
Independent Director
Click to see more

Key facts

  • EPIC
    NURO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    US6412558800
  • Market cap
    $9.01m
  • Employees
    13
  • Shares in issue
    2.06m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.